SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+1.77%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$224M
AUM Growth
+$224M
(+22%)
Cap. Flow
+$35.1M
Cap. Flow
% of AUM
15.71%
Top 10 Holdings %
Top 10 Hldgs %
46.72%
Holding
49
New
10
Increased
17
Reduced
7
Closed
1
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$4.49M |
| 2 |
Revvity
RVTY
|
$4.35M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
$4.34M |
| 4 |
Repligen
RGEN
|
$3.73M |
| 5 |
Universal Health Services
UHS
|
$3.62M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$5.15M |
| 2 |
Encompass Health
EHC
|
$3.26M |
| 3 |
Baxter International
BAX
|
$3.03M |
| 4 |
Boston Scientific
BSX
|
$2.15M |
| 5 |
Cardinal Health
CAH
|
$840K |
Sector Composition
| 1 | Healthcare | 90.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $20.7M | 5.64% |
250,000
| – | – |
|
2
Tenet Healthcare
THC
$16.3B
| $15M | 4.07% |
85,000
+15,000
| +21% | +$2.64M |
|
3
HCA Healthcare
HCA
$94.5B
| $9.58M | 2.61% |
25,000
| – | – |
|
4
McKesson
MCK
$85.4B
| $9.53M | 2.59% |
13,000
+2,000
| +18% | +$1.47M |
|
|
5
Universal Health Services
UHS
$11.6B
| $9.51M | 2.59% |
52,500
+20,000
| +62% | +$3.62M |
|
|
6
Boston Scientific
BSX
$156B
| $8.59M | 2.34% |
80,000
-20,000
| -20% | -$2.15M |
|
7
Eli Lilly
LLY
$657B
| $8.58M | 2.33% |
11,000
+2,000
| +22% | +$1.56M |
|
8
Danaher
DHR
$147B
| $7.9M | 2.15% |
40,000
+5,000
| +14% | +$988K |
|
|
9
Cardinal Health
CAH
$35.5B
| $7.56M | 2.06% |
45,000
-5,000
| -10% | -$840K |
|
10
Stryker
SYK
$150B
| $7.52M | 2.05% |
19,000
+1,500
| +9% | +$593K |
|
11
Cencora
COR
$56.5B
| $7.5M | 2.04% |
25,000
| – | – |
|
12
Intuitive Surgical
ISRG
$170B
| $7.06M | 1.92% |
13,000
-1,000
| -7% | -$543K |
|
13
Medtronic
MDT
$119B
| $6.97M | 1.9% |
80,000
+5,000
| +7% | +$436K |
|
14
Novo Nordisk
NVO
$251B
| $6.9M | 1.88% |
100,000
+30,000
| +43% | +$2.07M |
|
15
Humana
HUM
$36.5B
| $6.6M | 1.8% |
27,000
+4,000
| +17% | +$978K |
|
16
Waters Corp
WAT
$18B
| $6.28M | 1.71% |
18,000
+1,000
| +6% | +$349K |
|
17
Gilead Sciences
GILD
$140B
| $5.54M | 1.51% |
50,000
+10,000
| +25% | +$1.11M |
|
18
Cigna
CI
$80.3B
| $5.46M | 1.48% |
16,500
+4,000
| +32% | +$1.32M |
|
19
Abbott
ABT
$231B
| $5.33M | 1.45% |
39,200
-5,800
| -13% | -$789K |
|
20
Agilent Technologies
A
$35.7B
| $5.31M | 1.44% |
45,000
-5,000
| -10% | -$590K |
|
21
UnitedHealth
UNH
$281B
| $4.68M | 1.27% |
15,000
+10,000
| +200% | +$3.12M |
|
22
Select Medical
SEM
$1.61B
| $4.55M | 1.24% |
300,000
+100,000
| +50% | +$1.52M |
|
|
23
Quest Diagnostics
DGX
$20.3B
| $4.49M | 1.22% |
+25,000
| New | +$4.49M |
|
|
24
Revvity
RVTY
$10.5B
| $4.35M | 1.18% |
+45,000
| New | +$4.35M |
|
|
25
Bio-Rad Laboratories Class A
BIO
$8.06B
| $4.34M | 1.18% |
+18,000
| New | +$4.34M |
|